{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:12:06Z","timestamp":1792699926079,"version":"4.5.0"},"reference-count":30,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T00:00:00Z","timestamp":1592870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"HHS | Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["HHSO100201300011C"],"award-info":[{"award-number":["HHSO100201300011C"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,6,23]]},"abstract":"<jats:p>\n                    Gepotidacin, a triazaacenaphthylene bacterial type II topoisomerase inhibitor, is in development for treatment of uncomplicated urinary tract infection (uUTI). This phase 2a study in female participants with uUTI evaluated the pharmacokinetics (primary objective), safety, and exploratory efficacy of gepotidacin. Eligible participants (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200922) were confined to the clinic at baseline, received oral gepotidacin at 1,500\u2009mg twice daily for 5\u2009days (on-therapy period; days 1 to 5), and returned to the clinic for test-of-cure (days 10 to 13) and follow-up (day 28\u2009\u00b1\u20093) visits.\n                  <\/jats:p>","DOI":"10.1128\/aac.00199-20","type":"journal-article","created":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T10:19:37Z","timestamp":1586600377000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":47,"title":["Phase 2a Pharmacokinetic, Safety, and Exploratory Efficacy Evaluation of Oral Gepotidacin (GSK2140944) in Female Participants with Uncomplicated Urinary Tract Infection (Acute Uncomplicated Cystitis)"],"prefix":"10.1128","volume":"64","author":[{"given":"J. Scott","family":"Overcash","sequence":"first","affiliation":[{"name":"eStudySite, La Mesa, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney A.","family":"Tiffany","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole E.","family":"Scangarella-Oman","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline R.","family":"Perry","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Tao","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Hossain","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Barth","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne F.","family":"Dumont","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199310283291808"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.12.1583"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1047-2797(00)00072-7"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1104429"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2014.07.005"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02897-15"},{"key":"e_1_3_3_8_2","unstructured":"Centers for Disease Control and Prevention. 2019. Antibiotic resistance threats in the United States. https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf."},{"key":"e_1_3_3_9_2","unstructured":"World Health Organization. 2017. Global priority list of antibiotic resistant bacteria to guide research discovery and development of new antibiotics. http:\/\/www.who.int\/medicines\/publications\/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1804.111627"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00125-13"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01338-09"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature09197"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02820-15"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00468-17"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.8b00315"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02095-16"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy145"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01221-18"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00086-19"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2015.1112933"},{"key":"e_1_3_3_22_2","unstructured":"Tiffany CA Hossain M McDonald M Patel A Lerman S Patel P Widdowson KL Dumont EF. 2013. Safety and pharmacokinetics of single escalating oral doses of GSK2140944 a novel bacterial topoisomerase inhibitor. Abstr 53rd Intersci Conf Antimicrob Agents Chemother abstr F-1218."},{"key":"e_1_3_3_23_2","unstructured":"Tiffany CA Hossain M McDonald M Lerman S Dumont EF. 2014. Safety and pharmacokinetics of single escalating IV doses of GSK2140944 a novel bacterial topoisomerase inhibitor. Abstr 54th Intersci Conf Antimicrob Agents Chemotherapy abstr F-277."},{"key":"e_1_3_3_24_2","unstructured":"Tiffany CA Hossain M McDonald M Lerman S Dumont EF. 2014. Safety and pharmacokinetics of repeat escalating IV doses of GSK2140944 a novel bacterial topoisomerase inhibitor. Abstr 54th Intersci Conf Antimicrob Agents Chemotherapy abstr F-278."},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02385-16"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00115-16"},{"key":"e_1_3_3_27_2","volume-title":"STD Prevention Conf","author":"VanScoy BD","year":"2018","unstructured":"VanScoy BD, Fikes S, Bhavnani SM, Conde H, Scangarella-Oman NE, Ambrose PG. 2018. A hollow-fiber infection model to evaluate the prevention of on-therapy resistance of Neisseria gonorrhoeae to gepotidacin, poster 314. STD Prevention Conf, Washington, DC, 27 to 30 August 2018. https:\/\/www.fibercellsystems.com\/wp-content\/uploads\/2018\/09\/00479_gepo_gc_hfim_16aug18.pdf."},{"key":"e_1_3_3_28_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 11th ed. Document M07-A11. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"11"},{"key":"e_1_3_3_29_2","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2019","unstructured":"Clinical and Laboratory Standards Institute. 2019. Performance standards for antimicrobial susceptibility testing, 29th ed. Document M100-S29. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"29"},{"key":"e_1_3_3_30_2","unstructured":"Food and Drug Administration Center for Drug Evaluation and Research. 2019. Uncomplicated urinary tract infections: developing drugs for treatment. https:\/\/www.fda.gov\/media\/129531\/download."},{"key":"e_1_3_3_31_2","unstructured":"European Medicines Agency. 2018. Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections rev 3. EMA\/844951\/2018 rev 3. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections-revision-3_en.pdf."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00199-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00199-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:46:00Z","timestamp":1645461960000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00199-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,23]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,6,23]]}},"alternative-id":["10.1128\/AAC.00199-20"],"URL":"https:\/\/doi.org\/10.1128\/aac.00199-20","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,23]]},"assertion":[{"value":"2020-01-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00199-20"}}